Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

• Status: Completed
• Trial end date: 2012-06-01

Summary

The purpose of this study was to assess efficacy and tolerability of travoprost 0.004% vs. bimatoprost 0.01% during the after office hour period (4 pm to 8 pm) in subjects with open-angle glaucoma or ocular hypertension after 6 weeks of treatment.

• Phase: Phase 4

Details

• Lead Sponsor: Alcon Research
• Treatments: Bimatoprost; Ophthalmic Solutions; Pharmaceutical Solutions; Travoprost